Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank 指定難病告示番号
1 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02147 Salbutamol 14件: 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299
2 ABAT 7件: Alanine, aspartate and glutamate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, Propanoate metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse D00399 Valproic acid 17件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
3 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
4 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
5 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
6 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
7 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
8 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
9 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
10 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
11 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
12 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
13 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
14 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
15 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
16 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
17 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
18 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
19 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
20 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
21 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
22 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
23 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
24 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
25 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
26 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
27 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
28 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
29 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
30 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
31 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
32 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
33 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
34 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
35 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
36 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
37 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
38 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
39 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
40 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
41 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
42 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
43 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
44 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
45 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
46 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
47 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
48 GAD1 7件: Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus D00399 Valproic acid 17件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
49 GAD2 7件: Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus D00399 Valproic acid 17件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
50 MSTN 1件: Cytokine-cytokine receptor interaction D11797 Apitegromab 1件: 3
51 GHR 5件: Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action D02691 Somatotropin 23件: 2, 3, 13, 19, 46, 65, 74, 75, 76, 78, 96, 107, 113, 187, 191, 193, 195, 236, 238, 265, 274, 276, 299
52 GNRHR 2件: Neuroactive ligand-receptor interaction, GnRH signaling pathway D00989 Leuprolide 5件: 1, 2, 3, 51, 76
53 GRIA1 14件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
54 GRIA2 15件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
55 GRIA3 13件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
56 GRIA4 10件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
57 GRIK1 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
58 GRIK2 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
59 GRIK3 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
60 GRIK4 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
61 GRIK5 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
62 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
63 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
64 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
65 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
66 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
67 NR3C1 1件: Neuroactive ligand-receptor interaction D00472 Prednisolone 43件: 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
68 NR3C1 1件: Neuroactive ligand-receptor interaction D00980 Prednisolone 43件: 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
69 NR3C1 1件: Neuroactive ligand-receptor interaction D00981 Prednisolone 43件: 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
70 NR3C1 1件: Neuroactive ligand-receptor interaction D00982 Prednisolone 43件: 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
71 NR3C1 1件: Neuroactive ligand-receptor interaction D01239 Prednisolone 43件: 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
72 NR3C1 1件: Neuroactive ligand-receptor interaction D01998 Prednisolone 43件: 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
73 NR3C1 1件: Neuroactive ligand-receptor interaction D02156 Prednisolone 43件: 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
74 NR3C1 1件: Neuroactive ligand-receptor interaction D03301 Prednisolone 43件: 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
75 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00075 Testosterone 9件: 1, 2, 3, 13, 60, 76, 78, 113, 265
76 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00957 Testosterone 9件: 1, 2, 3, 13, 60, 76, 78, 113, 265
77 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00958 Testosterone 9件: 1, 2, 3, 13, 60, 76, 78, 113, 265
78 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00959 Testosterone 9件: 1, 2, 3, 13, 60, 76, 78, 113, 265
79 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D06085 Testosterone 9件: 1, 2, 3, 13, 60, 76, 78, 113, 265
80 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D06087 Testosterone 9件: 1, 2, 3, 13, 60, 76, 78, 113, 265
81 KCNA4 2件: Cortisol synthesis and secretion, Cushing syndrome D04127 Dalfampridine 5件: 3, 4, 6, 13, 14
82 KCNA4 2件: Cortisol synthesis and secretion, Cushing syndrome D10228 Amifampridine 3件: 3, 11, 12
83 KCNC3 1件: Spinocerebellar ataxia D04127 Dalfampridine 5件: 3, 4, 6, 13, 14
84 KCNC3 1件: Spinocerebellar ataxia D10228 Amifampridine 3件: 3, 11, 12
85 KCND2 1件: Serotonergic synapse D04127 Dalfampridine 5件: 3, 4, 6, 13, 14
86 KCND2 1件: Serotonergic synapse D10228 Amifampridine 3件: 3, 11, 12
87 KCND3 1件: Spinocerebellar ataxia D04127 Dalfampridine 5件: 3, 4, 6, 13, 14
88 KCND3 1件: Spinocerebellar ataxia D10228 Amifampridine 3件: 3, 11, 12
89 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D00487 Pyridostigmine 4件: 3, 6, 11, 256
90 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
91 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
92 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
93 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00217 Acetaminophen 18件: 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337
94 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00217 Acetaminophen 18件: 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337
95 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00567 Celecoxib 10件: 2, 3, 34, 46, 70, 89, 107, 161, 171, 271
96 RRM2 6件: Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways, p53 signaling pathway D00341 Hydroxyurea 8件: 3, 13, 19, 20, 65, 85, 86, 284
97 SMN1 - D11559 Onasemnogene abeparvovec 1件: 3
98 SMN2 - D10881 Nusinersen 1件: 3
99 SMN2 1件: Nucleocytoplasmic transport D11406 Risdiplam 1件: 3
100 TNNC2 1件: Calcium signaling pathway D11363 Reldesemtiv 1件: 3
101 ALDH5A1 3件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, Metabolic pathways D00399 Valproic acid 17件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
102 CACNA1I 7件: MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00399 Valproic acid 17件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
103 CACNA1H 7件: MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00399 Valproic acid 17件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
104 CACNA1G 8件: MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome D00399 Valproic acid 17件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331